Pharmaceuticals
China Biologic Products to Report Second Quarter 2020 Financial Results
BEIJING, Aug. 10, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the Company plans to release its second quarter 2020 financial results ...
2020-08-10 20:00
8887
BD Announces Voluntary Recall of ChloraPrep™ 3 mL Applicator in Specific U.S. Territories, Countries and Regions
FRANKLIN LAKES, New Jersey, Aug. 7, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company), a leading global medical technology company,announced a voluntary recall onJune 23, 2020 for specified catalog numbers of the ChloraPrep™ 3 mL applicator due to possible fungal contamination, which only a...
2020-08-07 18:59
3703
CMAB Appoints Ms. Maggie Chen as Chief Financial Officer
SUZHOU, China, Aug. 6, 2020 /PRNewswire/ -- CMAB Biopharma (Suzhou) Inc. ("CMAB"), a dedicated biologics contract manufacturing and development organization (CDMO), today announced the appointment of Ms.Maggie Chen as the chief financial officer. Ms. Chen will lay a solid foundation for the long-...
2020-08-07 08:00
4619
Dietary cholesterol and phytosterols contribute directly to heart disease
Genetic variability in cholesterol and phytosterol absorption affects cardiovascular disease risk REYKJAVIK, Iceland, Aug. 7, 2020 /PRNewswire/ -- Scientists at deCODE genetics , a subsidiary of Amgen, and their collaborators fromthe Icelandic healthcare system, University of Iceland, the Copenha...
2020-08-07 01:21
5651
ImmVira and Shanghai Pharma Announce Clinical Collaboration and License Agreement for Commercialization of Novel Intratumoral Oncolytic Virus Immunotherapies
SHENZHEN and SHANGHAI, August 6, 2020 /PRNewswire/ -- ImmVira Group Company and Shanghai Pharmaceuticals Holding Co., Ltd today announced a clinical collaboration and exclusive license agreement for ImmVira's MVR-T3011 intratumoral oncolytic virus program for the commercialization of novel immun...
2020-08-06 23:49
9555
I-Mab to Report Financial Results for the Six Months Ended June 30, 2020 and Provide Corporate Update on August 31, 2020
SHANGHAI and GAITHERSBURG, Md., Aug. 6, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will report financial results for the six months ...
2020-08-06 20:30
14838
Caprion-HistoGeneX and Viroclinics-DDL announce a strategic partnership to offer integrated, complementary services to advance infectious disease research and COVID-19 therapeutic development
Caprion-HistoGeneX, a specialized CRO providing immunology, proteomics, histopathology and genomics services, and Viroclinics-DDL, a provider of preclinical and clinical trial services for vaccine, antiviral, and diagnostic development, are pleased to announce a new partnership that will offer gl...
2020-08-06 20:10
2828
WuXi Vaccines Appoints Mr. Jian Dong as Chief Executive Officer
SHANGHAI and DUNDALK, Ireland, Aug. 6, 2020 /PRNewswire/ -- WuXi Vaccines, a global leading company with world-class vaccine contract development and manufacturing organization (CDMO) capabilities, is pleased to announce the appointment of Mr.Jian Dong as Chief Executive Officer (CEO). WuXi Vacci...
2020-08-06 17:00
3214
Samsung Biologics launches S-CHOice cell line expression technology
INCHEON, South Korea, Aug. 4, 2020 /PRNewswire/ -- Samsung Biologics (KRX:
207940.KS) today held an online ceremony to announce the launch of its
proprietary cell line technology, S-CHOice.
2020-08-05 09:09
2926
Colorcon Opens New Technical Centre in Melbourne, Australia to support the growing local pharmaceutical industry
HARLEYSVILLE, Penn., Aug. 5, 2020 /PRNewswire/ -- Colorcon, a world leader in the development and supply of film coating systems and excipients, today announces the opening of a new technical center inMelbourne, Australia. The facility provides customers in Australasia access to pharmaceutical cl...
2020-08-05 05:00
3467
China NMPA Accepts IND Application for Eftansomatropin Pivotal Trial in Pediatric Patients with Growth Hormone Deficiency
SHANGHAI and GAITHERSBERG, Md., Aug. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the China National Medical Products Administration (...
2020-08-04 20:17
15875
New data independently confirms and extends laboratory findings and expands safety profile of ATH434
MELBOURNE, Australia and SAN FRANCISCO, Aug. 3, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced that new clinical and experimental pharmacology data for its lead drug candidate ATH434 (formerly PBT434) has been selected for present...
2020-08-04 09:33
7662
TB Alliance Announces European Commission Authorisation of New Treatment for Highly Drug-Resistant Tuberculosis
Pretomanid, developed by the non-profit TB Alliance, has received EU marketing authorisation in combination regimen with bedaquiline and linezolid in adults with XDR-TB or treatment-intolerant/non-responsive MDR-TB PRETORIA, South Africa, Aug. 3, 2020 /PRNewswire/ -- Pretomanid, a novel compound...
2020-08-03 21:13
3023
Innovent Announces First Patient Dosed in the Phase 1 Clinical Trial of Anti-CD47/PD-L1 Bispecific Antibody in China
SUZHOU, China, Aug. 3, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major dise...
2020-08-03 08:00
9064
111 to Announce Second Quarter 2020 Unaudited Financial Results on August 20, 2020
SHANGHAI, July 31, 2020 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a Company dedicated to digitally connecting patients with drugs and healthcare services inChina, today announced that it will report its unaudited financial results for the second quarter endedJune 30, 2020, ...
2020-07-31 18:00
9933
Harbour BioMed Announces Strategic Partnership with Viva Biotech to Collaborate on Incubating Innovative Biotech Start-ups
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, SHANGHAI, China, July 31, 2020 /PRNewswire/ -- Harbour BioMed (HBM), a global clinical stage biopharmaceutical company and Viva Biotech (Shanghai) Ltd. ("Viva Biotech"), a world-leading structure-based drug discovery platform today announced...
2020-07-31 08:56
5485
Ascletis' All-oral HCV Treatment Approved for Marketing in China
HANGZHOU and SHAOXING, China, July 31, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that its all-oral HCV treatment has been approved for marketing inChina by National Medical Products Administration (NMPA). The Company's all-oral HCV treatment (RDV/DNV Regimen) is ...
2020-07-31 08:47
9971
Alterity Releases Appendix 4C - Q4 FY20 Quarterly Cash Flow Report
Highlights: * FDA provides guidance for ATH434 development pathway * Company compliant with minimum NASDAQ price * End of period cash balance of $9.2M bolstered by $1.5M following issue of shares on 2 July MELBOURNE, Australia and SAN FRANCISCO, July 30, 2020 /PRNewswire/ -- Alterity Therap...
2020-07-31 06:49
16981
INOVIO's COVID-19 DNA Vaccine INO-4800 Provides Protection with Memory Immune Responses In Non-Human Primates Challenged with SARS-CoV-2 Virus
- INO-4800 showed durable antibody and T cell responses in rhesus macaques for 4 months - INO-4800 is the only vaccine to demonstrate long-term protection in non-human primates challenged with SARS-CoV-2 virus 13 weeks from vaccination - Memory T and B cell responses resulted in reduced viral l...
2020-07-30 20:34
6067
Single Dose of Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-clinical Studies
Study published in Nature shows J&J's investigational SARS-CoV-2 vaccine elicits a strong immune response that protects against subsequent infection First-in-human Phase 1/2a clinical trial now underway in United States and Belgium; Phase 3 clinical trial expected to commence in September NEW BR...
2020-07-30 17:55
10447
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
6494
